Get the Stockscreener App
2.10
1.94%
0.04
Citius Oncology Inc stock is traded at $2.10, with a volume of 110.21K.
It is up +1.94% in the last 24 hours and down -60.30% over the past month.
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
See More
Previous Close:
$2.06
Open:
$2.06
24h Volume:
110.21K
Relative Volume:
0.07
Market Cap:
$163.79M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+12.30%
1M Performance:
-60.30%
6M Performance:
+66.67%
1Y Performance:
+0.00%
1-Day Range:
$2.05
$2.12
1-Week Range:
$1.8164
$2.37
52-Week Range:
$0.5506
$6.19
Citius Oncology Inc Stock (CTOR) Company Profile
Name
Citius Oncology Inc
Sector
Phone
(908) 967-6677
Address
11 COMMERCE DRIVE, CRANFORD
Compare CTOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
2.09 | 161.44M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
150.98 | 65.61B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.18 | 44.72B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.465 | 43.39B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.55 | 17.64B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
291.22 | 13.31B | 2.99B | 1.21B | 1.13B | 25.06 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-27-24 | Initiated | Maxim Group | Buy |
Citius Oncology Inc Stock (CTOR) Latest News
What analysts say about Citius Oncology Inc. stockMaximize gains with proven stock analysis - jammulinksnews.com
What institutional investors are buying Citius Oncology Inc. stockInvest smarter with expert stock recommendations - jammulinksnews.com
What is the risk reward ratio of investing in Citius Oncology Inc. stockUnlock exclusive trading strategies for gains - jammulinksnews.com
How volatile is Citius Oncology Inc. stock compared to the marketGet professional advice for portfolio optimization - jammulinksnews.com
Does Citius Oncology Inc. stock perform well during market downturnsUnlock real-time stock alerts for quick profits - jammulinksnews.com
How strong is Citius Oncology Inc. company’s balance sheetSkyrocketing returns - jammulinksnews.com
What are the latest earnings results for Citius Oncology Inc.Free Stock Market Trend Analysis - jammulinksnews.com
Why is Citius Oncology Inc. stock attracting strong analyst attentionAchieve breakthrough investment performance - jammulinksnews.com
What is Citius Oncology Inc. company’s growth strategyBuild a portfolio for long-term financial success - jammulinksnews.com
Should I hold or sell Citius Oncology Inc. stock in 2025Capitalize on market trends early - jammulinksnews.com
What drives Citius Oncology Inc. stock priceGet timely market insights for better trades - jammulinksnews.com
What are analysts’ price targets for Citius Oncology Inc. in the next 12 monthsFree Daily Trading Room Entry - jammulinksnews.com
How does Citius Oncology Inc. compare to its industry peersBreakthrough stock performance - jammulinksnews.com
How does Citius Oncology Inc. generate profit in a changing economyPost Market Target Finder To Watch Now - jammulinksnews.com
What makes Citius Oncology Inc. stock attractive to long term investorsPortfolio Diversification Stock Ideas From Experts - metal.it
Published on: 2025-07-29 19:38:23 - metal.it
Trendline Breach Raises Concern for Citius Oncology Inc. InvestorsFundamental + Technical Hybrid Stock Tips Shared - metal.it
Citius Oncology Inc. Stock Support and Resistance Levels You Should KnowVerified Return Tips - metal.it
Is Citius Oncology Inc. a good long term investmentExceptional trading performance - Autocar Professional
Citius Oncology Announces Closing of $9.0 Million Public Offering - StreetInsider
Citius Oncology Inc. Stock Analysis and ForecastMarket-leading capital gains - Autocar Professional
Citius Oncology shares surge 50.91% intraday after signing LYMPHIR distribution agreement with Cencora. - AInvest
Citius Oncology Inc Stock (CTOR) Financials Data
There is no financial data for Citius Oncology Inc (CTOR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.65%
0.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):